CClinicalTrials.gg
CompletedNCT03538496Updated May 10, 2019

Comparison of Erector Spinae Plane Block With Thoracic Paravertebral Block for Video Assisted Thoracoscopic Surgery

An interventional study of Bupivacaine Hcl 0.25% Inj in Postoperative Pain, sponsored by Ataturk University. Completed at 1 site in Turkey. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2019-05-10.

Sponsored by Ataturk University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Dec 2017, registered May 2018).
Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Erector Spinae Plane Block (ESPB) is a newly described and effective interfascial plane block for thoracic and abdominal surgery. It was first described by Forero et al. in 2016, effectiveness being reported in four cases. The paravertebral block has been successfully used in various surgical patient groups for purposes of anesthesia or postoperative pain management such as thoracotomy, breast surgery and abdominal surgery. The aim of this study is to compare the analgesic effects of erector spinae plane block and paravertebral block in patients undergoing video assisted thoracoscopic surgery.

02

Conditions studied

  • Postoperative Pain

Browse trials for

03

In context

Pain, Postoperative

5,093 studies on the registry are indexed under Pain, Postoperative; 1,140 are open to participants now.

This study's enrollment of 60 is below the median of 75 across 4,344 interventional studies indexed under Pain, Postoperative.

Browse Pain, Postoperative studies →

Lead sponsor

Ataturk University is the lead sponsor of 442 studies on the registry; 121 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • American Society of Anesthesiologist's physiologic state I-III patients
  • Undergoing video assisted thoracoscopic surgery

Exclusion criteria

Exclusion Criteria:

  • chronic pain
  • bleeding disorders
  • renal or hepatic insufficiency
  • patients on chronic non-steroidal anti-inflammatory medications
  • emergency cases
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
60 participants (actual)

Study arms

  • Active comparator
    ultrasound guided erector spinae plane block

    ultrasound guided erector spinae plane block with 20 ml %0.25 bupivacaine

    Drug: Bupivacaine Hcl 0.25% Inj

  • Active comparator
    ultrasound guided paravertebral block

    ultrasound guided paravertebral block with 20 ml %0.25 bupivacaine

    Drug: Bupivacaine Hcl 0.25% Inj

Interventions

  • DrugBupivacaine Hcl 0.25% Inj

    Single shot 20 ml 0.25 bupivacaine

06

What researchers measure

Primary outcomes

  1. Postoperative opioid consumption

    First 24 hours total fentanyl consumption with patient controlled analgesia

    Time frame: First 24 hours

Secondary outcomes

  1. Visual analog pain score

    Post operative pain will be evaluated with a Visual Analogue Scale (VAS) score of 0-10 (0= no pain and 10= worst imaginable pain)

    Time frame: postoperative 0-24 hours

  2. Block performing time

    The block time was defined as the period between the insertion of the needle and termination of local anesthetic administration

    Time frame: First hour

07

Study locations

1 site
  • Ataturk University
    Erzurum, 25100, Turkey
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 10, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03538496
Lead sponsor
Ataturk University
Responsible party
Ali Ahiskalioglu (Principal Investigator, Ataturk University) — Principal investigator
First posted
May 29, 2018
Start date
Dec 1, 2017
Primary completion
Sep 1, 2018
Completion
Sep 30, 2018
Last update
May 10, 2019

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion